Profound Medical (PROF)
Commercializes MRI-guided ultrasound platforms for prostate ablation and focused-ultrasound treatment.
$6.83
At close+0.03 (+0.44%)
In millions of USD, except per-share figures
| In millions | Q3 FY23Sep 2023 | Q4 FY23Dec 2023 | Q1 FY24Mar 2024 | Q2 FY24Jun 2024 | Q3 FY24Sep 2024 | Q4 FY24Dec 2024 | Q1 FY25Mar 2025 | Q2 FY25Jun 2025 | Q3 FY25Sep 2025 | Q4 FY25Dec 2025 | Q1 FY26Mar 2026 | Q2 FY26Jun 2026 |
|---|---|---|---|---|---|---|---|---|---|---|---|---|
| Revenue | 2 | 3 | 1 | 2 | 3 | 4 | 3 | 2 | 5 | 6 | 5 | 2 |
| Cost of revenue | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 1 | 2 | 1 | 1 |
| Gross profit | 1 | 1 | 1 | 1 | 2 | 3 | 2 | 2 | 4 | 4 | 4 | 2 |
| 8 | 66 | 9 | 9 | 12 | 11 | 13 | 15 | 13 | 11 | 12 | 13 | |
| Research & development | 3 | 5 | 4 | 4 | 6 | 5 | 5 | 6 | 5 | 4 | 5 | 6 |
| 4 | 17 | 5 | 5 | 7 | 6 | 8 | 9 | 7 | 7 | 6 | 7 | |
| Selling & marketing | 2 | 9 | 2 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| General & administrative | 2 | 8 | 2 | 0 | 0 | 0 | 0 | 0 | 7 | 0 | 0 | 7 |
| Other expenses | 0 | 43 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Operating income | −7 | −64 | −8 | −8 | −10 | −8 | −11 | −14 | −9 | −7 | −8 | −11 |
| 1 | 52 | 1 | 1 | 1 | 3 | 0 | −2 | 1 | −1 | 1 | 2 | |
| Interest income | 1 | 0 | 1 | 1 | 1 | −2 | 0 | 0 | 0 | 0 | 0 | 0 |
| Interest expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Other non-operating income | 0 | −53 | 0 | −1 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | −2 |
| Income before tax | −6 | −12 | −7 | −7 | −9 | −6 | −11 | −16 | −8 | −8 | −7 | −9 |
| Income tax expense | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 | 0 |
| Net income from continuing operations | −6 | −11 | −7 | −7 | −9 | −5 | −11 | −16 | −8 | −8 | −7 | −10 |
| Net income | −6 | −11 | −7 | −7 | −9 | −5 | −11 | −16 | −8 | −8 | −7 | −10 |
| EPS, basic | −$0.26 | −$0.43 | −$0.26 | −$0.28 | −$0.38 | −$0.21 | −$0.36 | −$0.52 | −$0.27 | −$0.27 | −$0.19 | −$0.26 |
| EPS, diluted | −$0.26 | −$0.43 | −$0.26 | −$0.28 | −$0.38 | −$0.21 | −$0.36 | −$0.52 | −$0.27 | −$0.27 | −$0.19 | −$0.26 |
| Weighted average shares, basic | 21 | 21 | 24 | 24 | 25 | 26 | 30 | 30 | 30 | 31 | 36 | 36 |
| Weighted average shares, diluted | 21 | 21 | 24 | 24 | 25 | 26 | 30 | 30 | 30 | 31 | 36 | 36 |
| EBITDA | −6 | −11 | −8 | −7 | −10 | −8 | −11 | −14 | −9 | −7 | −8 | −9 |
| Depreciation & amortization | 0 | 0 | 0 | 0 | 0 | 1 | 0 | 0 | 0 | 0 | 0 | 0 |
| EBIT | −7 | −12 | −8 | −7 | −10 | −8 | −11 | −14 | −9 | −7 | −8 | −9 |